Alkermes submits supplemental new drug application to FDA
Tuesday, August 09, 2016
Alkermes submits supplemental new drug application to FDA for two month dosing option of Aristada for treatment of schizophrenia.
Notice of allowance issued for Aristada patent application, extending expected protection into 2035. Expects patent to issue within next few months and expire no earlier than march 2035.
Source : reuters.com
